through the generation of a reactive enamine intermediate.9
We report here that N-heterocyclic carbenes (NHCs) catalyze
the formation of enolates/enols through an elimination
process of R-aryloxy aldehydes. The capture of these
nucleophiles leads to substituted coumarins by a domino
Michael addition/acylation process (eq 1 in Scheme 1).
Scheme 2. Proposed Reaction Pathway
Scheme 1. General Concept
group (e.g., chloride or sulfonate) would potentially initiate
the reaction faster (I to II and III) but would fail to turn
over the catalyst due to weak nucleophilicity (IV to 2).
Enone 1a was chosen to explore this carbene-catalyzed
enolate formation strategy and leads to the formation of 3,4-
dihydrocoumarin products.14 Substituted coumarins and
related compounds are biologically active,15 and access to
this particular substitution pattern by Michael additions
to the parent coumarin remains challenging.16 For example,
to the best of our knowledge, there are no general and high-
yielding reports of conjugate additions of enolates to cou-
marins. While combining enone 1a with imidazolium or
benzimidazolium salts in the presence of base produced a
minor amount of the desired product (entries 1 and 2, Table
1), a large increase in yield was observed when triazolium
precatalyst C17 was used with DBU (entry 5). Further
optimization revealed that acetonitrile was the best solvent
(60% yield, entry 6). In this particular case, the moderate
yield was due to decomposition from prolonged exposure
to silica gel. Indeed, quick filtration through SiO2 provided
an improved 83% yield of pure desired product 2a
(entry 7).
In our recent carbene catalysis studies to access enols by
the protonation of homoenolates,10 we became interested in
whether new carbon-carbon bond-forming reactions were
possible using reactive acetate-type enol-NHC intermediates
from R-aryloxyacetaldehydes. This concept is distinctive
since the phenol in the R-position serves an important dual
purpose: first to facilitate generation of the enol equivalent
and second to liberate the carbene catalyst through an
acylation event.11 We hypothesized that this process could
be evaluated with an aldehyde containing a tethered conju-
gate acceptor in the ortho-position.12 The likely pathway
involves initial addition of the NHC to aldehyde 1 (Scheme
2).13 A formal 1,2-shift of the aldehyde proton results in
elimination of phenoxide/phenol derivative III and concomi-
tant formation of enol equivalent II. A Michael addition
could then occur which, when followed by intramolecular
O-acylation, promotes regeneration of the carbene catalyst.
A delicate balance of leaving group ability and nucleophi-
licity of the R-position substituent is crucial. A catalytic
process is untenable if these factors are not optimal in this
new type of “rebound” process. For example, a strong leaving
With azolium salt C identified as the most efficient
precatalyst to promote this well-orchestrated domino process,
we investigated the scope of the reaction. Electron-withdraw-
ing (Table 2, entry 3) and electron-donating aryl ketones
(entries 4 and 5), as well as naphthyl ketones (entry 6), are
accommodated by the reaction conditions. Electron-with-
(9) List, B. Acc. Chem. Res. 2004, 37, 548–557.
(10) (a) Phillips, E. M.; Wadamoto, M.; Chan, A.; Scheidt, K. A. Angew.
Chem., Int. Ed. 2007, 46, 3107–3110. (b) Wadamoto, M.; Phillips, E. M.;
Reynolds, T. E.; Scheidt, K. A. J. Am. Chem. Soc. 2007, 129, 10098-10099.
For excellent reviews on carbene catalysis, see: (c) Enders, D.; Niemeier,
O.; Henseler, A. Chem. ReV. 2007, 107, 5606–5655. (d) Marion, N.; Diez-
Gonzalez, S.; Nolan, I. P. Angew. Chem., Int. Ed. 2007, 46, 2988–3000.
(11) For a review on domino reactions, see: (a) Tietze, L. F. Chem.
ReV. 1996, 96, 115-136. For NHC reactions using unstable a-chloroalde-
hydes in which the leaving group (chloride) is not involved in catalysts
turnover, see: (b) Reynolds, N. T.; Rovis, T. J. Am. Chem. Soc. 2005, 127,
16406–16407. (c) He, M.; Uc, G. J.; Bode, J. W. J. Am. Chem. Soc. 2006,
128, 15088–15089.
(14) (a) Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E.
Curr. Med. Chem. 2005, 12, 887–916. (b) Murray, R. D. H. Nat. Prod.
Rep. 1995, 12, 477–505.
(15) (a) Okuda, T.; Kimura, Y.; Yoshida, T.; Hatano, T.; Okuda, H.;
Arichi, S. Chem. Pharm. Bull. 1983, 31, 1625–1631. (b) Demir, A. S.; Gross,
R. S.; Dunlap, N. K.; Bashirhashemi, A.; Watt, D. S. Tetrahedron Lett.
1986, 27, 5567–5570. (c) Posakony, J.; Hirao, M.; Stevens, S.; Simon, J. A.;
Bedalov, A. J. Med. Chem. 2004, 47, 2635–2644.
(12) (a) Yang, J. W.; Chandler, C.; Stadler, M.; Kampen, D.; List, B.
Nature 2008, 452, 453–455. (b) Hayashi, Y.; Itoh, T.; Ohkubo, M.; Ishikawa,
H. Angew. Chem., Int. Ed. 2008, 47, 4722–4724.
(16) (a) Connor, R.; McClellan, W. R. J. Org. Chem. 1939, 3, 570–
577. (b) Dixon, D. J.; Horan, R. A. J.; Monck, N. J. T.; Berg, P. Org. Lett.
2004, 6, 4427–4429. (c) Matsuda, T.; Shigeno, M.; Murakami, M. J. Am.
Chem. Soc. 2007, 129, 12086–12087.
(13) Reynolds, T. E.; Stern, C. A.; Scheidt, K. A. Org. Lett. 2007, 9,
2581–2584.
(17) Chan, A.; Scheidt, K. A. J. Am. Chem. Soc. 2008, 130, 2740–2741.
106
Org. Lett., Vol. 11, No. 1, 2009